Hisamitsu Pharmaceutical Co Inc 2024 IR
The report outlines Hisamitsu Pharmaceutical Group's financial and non-financial performance for the fiscal year ended February 29, 2024. Key achievements include a sales growth rate of 7.4% and an overseas sales ratio of 42.8%, driven by the global expansion of its flagship brand, Salonpas. The company completed the SAGA Global Research Center in February 2024 to consolidate its domestic R&D functions and accelerate innovation. On the sustainability front, Hisamitsu reduced its Scope 1 and 2 CO2 emissions by 29.5% compared to the FY2013 baseline, progressing toward its 2030 reduction target of 46%.
Company: Hisamitsu Pharmaceutical Co Inc
Sector: Health Care
Country: Japan
Year: 2024
Type: IR
Pages: 36
Hisamitsu Pharmaceutical Co Inc
Integrated Report
The report outlines Hisamitsu Pharmaceutical Group's financial and non-financial performance for the fiscal year ended February 29, 2024. Key achievements include a sales growth rate of 7.4% and an overseas sales ratio of 42.8%, driven by the global expansion of its flagship brand, Salonpas. The company completed the SAGA Global Research Center in February 2024 to consolidate its domestic R&D functions and accelerate innovation. On the sustainability front, Hisamitsu reduced its Scope 1 and 2 CO2 emissions by 29.5% compared to the FY2013 baseline, progressing toward its 2030 reduction target of 46%.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Mar 1, 2023 - Feb 29, 2024
Fiscal Year
2023
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Water Consumption
Total Waste
Women in Management
Net Zero Target
Employees